Cite

    Brian Baker et al.. “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies.” Cephalalgia reports, vol. 5, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100169725485.0x000042